Cancer AI Alliance

What Cancer AI Alliance does

Cancer AI Alliance (CAIA) is a nonprofit research consortium founded in October 2024 by four National Cancer Institute-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center (the coordinating center), Memorial Sloan Kettering Cancer Center, and the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering. Its functional purpose is to remove data silos that have prevented cross-institutional oncology research by giving member-center researchers a federated learning platform that trains AI models against distributed patient data without sensitive records ever leaving institutional firewalls. End users are oncology researchers and clinicians at member cancer centers working on problems such as treatment-response prediction, biomarker discovery, rare-cancer analysis, and clinical decision support. The organization is supported by $65 million in philanthropic and in-kind commitments and governed by a Steering Committee of senior scientific and informatics leaders from each founding center.

The core platform combines NVIDIA FLARE as the federated learning runtime, the Rhino Federated Computing Platform as the user-facing orchestration portal, the OMOP Common Data Model for institutional data standardization, and edge nodes deployed at each participating cancer center to mediate local training and aggregation. A central orchestration layer coordinates model distribution and weighted aggregation without ever accessing underlying patient data. On top of this infrastructure CAIA runs a portfolio of pilot projects organized as four clinical innovation tracks (treatment response, novel biomarkers, rare cancers, treatment outcomes) and four AI innovation tracks (foundation model development for downstream researchers), and offers Asta DataVoyager—a plain-language, citation-backed query interface prototyped with Ai2. The platform also processes unstructured clinical text (pathology, radiology, physician notes) alongside structured records, with explicit roadmap expansion to genomics, digital pathology, and radiology imaging.

Name

Cancer AI Alliance

Legal name

Cancer AI Alliance

Website

https://canceralliance.ai

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Cancer AI Alliance is a nonprofit research consortium founded in October 2024 by four NCI-designated cancer centers (Dana-Farber, Fred Hutch, Memorial Sloan Kettering, Johns Hopkins) that operates a federated learning platform enabling AI model training on distributed clinical data across member institutions.

Ownership category

akta.pro rank

Product category

Cancer Research AI Platform

NAICS

Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Computer Integrated Systems Design (7373), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Federated learning platform
• Cancer research AI
• Multi-institutional data collaboration
• Privacy-preserving analytics
• Clinical data federation

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

1. Philanthropic Funding: CAIA has secured $65 million in philanthropic funding and in-kind support from technology industry leaders and philanthropist supporters to build and operate the federated learning platform for cancer research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

CAIA operates a multi-cloud federated learning platform that lets researchers at participating NCI-designated cancer centers train AI models on distributed clinical data without moving sensitive patient records outside institutional firewalls. The platform runs on NVIDIA FLARE and RhinoFCP, uses the OMOP Common Data Model for standardization, and supports clinical-innovation and AI-innovation pilot projects (e.g., treatment response prediction, biomarker discovery, foundation-model development) across four founding cancer centers covering more than one million patients.

Product overview

Cancer AI Alliance operates a unified platform approach centered on its multi-cloud federated learning platform, which enables collaborative cancer research across four National Cancer Institute-designated cancer centers. The platform consists of an orchestration layer that coordinates AI model training across edge nodes installed at each participating cancer center, supporting both clinical innovation projects (immediate patient care applications) and AI innovation projects (foundation model development for future research). The ecosystem also includes Asta DataVoyager, a plain-language query tool developed with Ai2. All products work together to enable cross-institutional AI research while keeping sensitive patient data within institutional firewalls.

Differentiator

Problem solved

Functional benefit

Products and services

• CAIA Federated Learning Platform
• Asta DataVoyager
• Eight Pilot Research Projects

Quantifiable outcome

• Accelerate pace of cancer discovery by up to tenfold
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 1 October 2024One of four founding National Cancer Institute-designated cancer centers of CAIA, providing clinical data and research expertise for federated learning platform development.
• Fred Hutch Cancer CentercoreStrategic or Co-development Partner · 1 October 2024Serves as the coordinating center for CAIA. Fred Hutch's leadership, including Jeff Leek as Scientific Director, has been central to the alliance's formation and operations.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 1 October 2024One of four founding NCI-designated cancer centers, contributing computational oncology expertise and clinical data to the federated learning platform.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Whiting School of EngineeringcoreStrategic or Co-development Partner · 1 October 2024Founding academic partner providing engineering expertise through the Malone Center for Engineering in Healthcare and data science capabilities from the Data Science and AI Institute.
• Ai2 (Allen Institute for AI)flagshipTechnology or Integration · 1 October 2024Providing state-of-the-art AI tools including Asta DataVoyager for plain-language querying across the federated platform, and technical expertise as part of the $65M in contributions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Deep 6 AI: Deep 6 AI uses NLP and AI to mine EHR data for clinical trial matching and cohort discovery at hospital systems. It overlaps with CAIA's structured + unstructured EHR analytic capabilities on the clinical research side.
• PathAI: PathAI applies AI to pathology and oncology diagnostics, with deployments at academic cancer centers and partnerships with pharma. It overlaps with CAIA's planned expansion into digital pathology slides and cancer biomarker AI.
• DNAnexus: DNAnexus operates a cloud-based biomedical data analysis and collaboration platform used for genomic and clinical research. It serves a similar 'multi-institutional biomedical data infrastructure' role as the RhinoFCP-based orchestration layer CAIA uses.

Direct peers

• Rhino Health: Rhino Health provides the Rhino Federated Computing Platform (RhinoFCP), the same orchestration infrastructure CAIA uses for federated learning. It is a technology partner of CAIA but also an explicit commercial peer offering federated AI deployment to hospitals and life sciences clients.
• Owkin: Owkin builds federated AI for oncology and other disease areas, including collaborations with major cancer centers. It is the closest direct comparable to CAIA in deploying privacy-preserving multi-institutional AI research models, though operating as a commercial entity.
• ConcertAI: ConcertAI builds AI software and real-world evidence platforms for oncology and clinical research. It works with cancer centers and pharma on AI-based precision oncology, partially overlapping with CAIA's focus areas.

Broad incumbents

• Tempus Labs: Tempus is a leading AI-driven precision medicine company focused on oncology, building foundation models and clinical decision support from molecular and clinical data. It serves as the principal commercial incumbent competing for the same use cases (treatment response, biomarker discovery) CAIA targets.
• Flatiron Health (Roche): Flatiron Health curates oncology-specific EHR data and analytics for research and clinical operations. Its deidentified real-world oncology dataset is highly comparable to CAIA's federated cross-institutional data and is a key data-source incumbent in oncology AI.
• Foundation Medicine (Roche): Foundation Medicine is a molecular information / genomic profiling company widely used in oncology practice. It operates a broad cancer genomics platform and represents an incumbent alternative data and AI infrastructure for precision oncology.
• Verily (Alphabet): Verily, an Alphabet life sciences company, develops AI/ML platforms and precision medicine initiatives across disease areas including oncology. It is a broad incumbent with overlapping AI and healthcare ambitions and is backed by Google — one of CAIA's philanthropic partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CAIAorg
• LinkedInlinkedin.com/company/cancer-ai-alliance

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer AI Alliance